METHOD FOR PREDICTION OF RISK OF SEVERE SECONDARY ANEMIA, REQUIRING BLOOD TRANSFUSION, IN YOUNG INFANTS UNDERGOING INTRAUTERINE BLOOD TRANSFUSION BECAUSE OF FETAL HEMOLYTIC DISEASE ON RHESUS FACTOR Russian patent published in 2018 - IPC G01N33/49 

FIELD: medicine.

SUBSTANCE: invention is a method for prediction of severe secondary anemia development, requiring blood transfusion, in young infants undergoing intrauterine transfusion (IUT) because of fetal hemolytic disease on the rhesus factor (HDN), which includes determination of the level of venous blood hematocrit at birth (A₁), determination of the average level of erythrocyte in venous blood on day 14-21 of life (A₂) calculation of the prognostic index (D) by the formula D=A₁×0.529-A₂×0.221+3.256 and prediction of a high risk of secondary anemia when D≥0, or prediction of the absence of secondary anemia when D<0.

EFFECT: method allows to allocate a risk group in terms of severe anemia development at the out-patient stage, in the neonatality period children with fetal hemolytic disease on the rhesus factor after prenatal intrauterine blood transfusion, which gives an opportunity to prevent the development of this state and narrow the range of children, requiring frequent study of hemogram.

2 ex